Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

Viking Therapeutics (VKTX) Tops Q4 EPS by 3c

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13).

"We made excellent progress with our lead programs in 2019, setting the company up for an exciting year in 2020," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "In the fourth quarter, we... More